Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, Scotiabank Analyst Says

Merck & Co., Inc. (NYSE:MRK) had its target price lifted by investment analysts at Scotiabank from $155.00 to $180.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “sector outperform” rating on the stock. Scotiabank’s price target indicates a potential upside of 22.81% from the company’s previous close.

MRK has been the topic of several other reports. HSBC upped their price target on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Royal Bank Of Canada cut shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and lifted their price objective for the stock from $142.00 to $150.00 in a research note on Thursday, August 20th. Leerink Partners boosted their price objective on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. TD Cowen increased their target price on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the stock a “hold” rating in a research report on Wednesday, September 23rd. Finally, Weiss Ratings raised shares of Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. Sixteen research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.76.

Merck & Co., Inc. Stock Performance

MRK traded down $2.12 during trading on Tuesday, hitting $146.57. The stock had a trading volume of 1,375,664 shares, compared to its average volume of 10,703,549. The company has a 50 day moving average price of $141.38 and a 200-day moving average price of $126.56. The firm has a market cap of $361.61 billion, a price-to-earnings ratio of 117.38, a P/E/G ratio of 6.48 and a beta of 0.21. Merck & Co., Inc. has a one year low of $78.39 and a one year high of $156.92. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current year.

Insider Buying and Selling

In related news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the sale, the executive vice president owned 18,212 shares in the company, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Richard R. Deluca sold 20,784 shares of Merck & Co., Inc. stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the transaction, the executive vice president directly owned 134,703 shares in the company, valued at $17,569,312.29. This trade represents a 13.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by company insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of large investors have recently modified their holdings of MRK. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Merck & Co., Inc. by 28.3% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 105,500 shares of the company’s stock valued at $13,557,000 after purchasing an additional 23,240 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Merck & Co., Inc. by 3.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,996,890 shares of the company’s stock worth $513,599,000 after buying an additional 143,914 shares in the last quarter. Andra AP fonden raised its holdings in shares of Merck & Co., Inc. by 6.8% during the 2nd quarter. Andra AP fonden now owns 389,285 shares of the company’s stock worth $50,023,000 after buying an additional 24,800 shares in the last quarter. State Street Corp lifted its position in shares of Merck & Co., Inc. by 0.9% during the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after buying an additional 1,087,583 shares during the last quarter. Finally, Security National Bank of SO Dak bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth $119,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck agreed to license SciBrunch Therapeutics’ experimental oral KRAS G12D inhibitor SPR2015 globally. The deal includes a $400 million upfront payment and could reach $2.13 billion based on development, regulatory and commercial milestones. The preclinical program could diversify Merck’s oncology pipeline and strengthen its position in a highly competitive cancer market. Merck licenses SciBrunch cancer drug deal
• Positive Sentiment: The FDA expanded Welireg’s label to include another advanced kidney-cancer indication, potentially broadening the drug’s commercial opportunity as sales grow. Merck also said CAPVAXIVE was added to Ontario’s publicly funded adult pneumococcal vaccination program, supporting wider vaccine access and demand. FDA expands Merck’s Welireg label
• Positive Sentiment: MSD began a Phase I trial of a drug candidate using Cyprumed’s oral delivery technology. The first program to reach human testing triggers a payment to Cyprumed and could eventually support more convenient oral formulations. Cyprumed oral delivery technology advances
• Neutral Sentiment: Merck’s remigromig program posted positive Phase 2b/3 BRUNELLO results in diabetic macular edema, but additional regulatory and commercial work is still needed before it can materially offset future revenue exposure.
• Neutral Sentiment: A Zacks screen identified Merck as a candidate to exceed quarterly earnings estimates, although the item provides no new company-specific operating results.
• Negative Sentiment: Merck and Daiichi Sankyo withdrew the U.S. application for ifinatamab deruxtecan in previously treated extensive-stage small-cell lung cancer after FDA discussions indicated that available Phase 2 evidence did not support accelerated approval. The setback delays a potential revenue contributor and removes an expected regulatory advantage over competitors, although late-stage studies continue. Merck and Daiichi end plans for speedy approval

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.